Plasmapheresis: a Multi-modal Approach

NCT ID: NCT05815615

Last Updated: 2023-04-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Only very few studies have prospectively looked at the effect of repeated intensive plasma donation. In collaboration with the Rode Kruis Vlaanderen, we have recently found that repeated whole blood donation with a 3-month interval in between induced a drop in markers for iron status, which worsened with the number of donations. The repetition effect of the donations, whether whole blood or plasma, can be different from the effects measured after one single donation. It is therefore critical to test and document this repetitive effect to build trustable and valid guidelines concerning repetitive plasma donation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Plasmapheresis Haematology Sport Performance Body Composition Inflammation Immunology Adverse Events

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Simulated plasma donation, same procedure as for plasmapheresis but without drawing blood.

Group Type PLACEBO_COMPARATOR

Plasmapheresis

Intervention Type DEVICE

Plasma donation at different frequencies

Low-frequency

Plasma donation 1x/month for 3 months

Group Type EXPERIMENTAL

Plasmapheresis

Intervention Type DEVICE

Plasma donation at different frequencies

High-frequency

Plasma donation 3x/month for 3 months

Group Type EXPERIMENTAL

Plasmapheresis

Intervention Type DEVICE

Plasma donation at different frequencies

US scheme

Plasma donation 2x/week for 3 months

Group Type EXPERIMENTAL

Plasmapheresis

Intervention Type DEVICE

Plasma donation at different frequencies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasmapheresis

Plasma donation at different frequencies

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* male,
* age between 18-50 years
* BMI between 20-28 kg/m2
* aptitude to perform maximal physical efforts assessed by the physical activity readiness questionnaire (PAR-Q)

Exclusion Criteria

* In case the subjects do not comply with the criteria of the Rode Kruis Vlaanderen, their plasma donations will be thrown away.
* In case the subjects comply, their plasma donations will be handled as usually.
* The criteria will be assessed before each plasma donation by a questionnaire as usually done in the Center of the Rode Kruis.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université Catholique de Louvain

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLouvain

Louvain-la-Neuve, Brabant Wallon, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RK2020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Hemochromatosis
NCT00007150 ACTIVE_NOT_RECRUITING PHASE2
Hemoglobin and Iron Recovery Study
NCT01555060 COMPLETED PHASE2
Iron Substitution in Blood Donors
NCT01519830 COMPLETED PHASE4